Rating Change
Chardan Capital analysts reiterated a Buy rating on Tenax Therapeutics, Inc. (NASDAQ:TENX) on July 02, 2026.
reiterateNASDAQ:TENX
Chardan Capital Reiterates Buy Rating on Tenax Therapeutics, Inc. (TENX)
Rating Change Chardan Capital analysts reiterated a Buy rating on Tenax Therapeutics, Inc. (NASDAQ:TENX) on July 02, 2026. Market Context Tenax Therapeutics, Inc.
Market Context
Tenax Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $14.48 with a market capitalization of $45.0M.
Analyst coverage from Chardan Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Tenax Therapeutics, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Tenax Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 02, 2026 | Chardan Capital | Buy | N/A |
| Jun 24, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Jun 22, 2026 | Chardan Capital | Buy | N/A |
| Jun 22, 2026 | Guggenheim | Buy | N/A |
| Jun 12, 2026 | Piper Sandler | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View TENX Stock Page
Frequently Asked Questions
What does a Buy rating mean for TENX?
A Buy rating from Chardan Capital reflects the analyst's outlook on Tenax Therapeutics, Inc. (NASDAQ:TENX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the TENX forecast page.